Bright Minds Biosciences announced positive Phase 2 results for its selective serotonin receptor agonist BMB‑101, showing clinically meaningful seizure reductions across two seizure types. The company said the mid‑stage data support progression to Phase 3 and will inform registrational trial design. Bright Minds emphasized safety and efficacy signals in its release; analysts flagged the result as a notable small‑cap readout that could shape future epilepsy development strategies. The company plans further regulatory discussions and a Phase 3 pathway after preparing a detailed data package.